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Invasive aspergillosis (IA) is a deep tissue infection with a high mortality occurring mostly
in immunocompromised patients. To investigate the pathology of patients with IA it
may be important to determine the genotype of the invasive isolate of Aspergillus,
however available tissues for study are often formalin fixed paraffin embedded (FFPE).
Although DNA has been successfully isolated from such tissues for species identification,
genotyping of Aspergillus species on such tissues has not yet been performed. In this
study we aimed to determine the genotype of Aspergillus fumigatus in FFPE tissue and
serum samples from five patients with invasive aspergillosis using nine highly polymorphic
short tandem repeat (STRAf ) loci. FFPE lung and bronchial biopsies from all patients
were successfully typed. By comparing the latter result with non-FFPE materials from
non-sterile samples such as sputum, bronchoalveolar lavage and lung abscess, we
found identical genotypes within three patients, while the two other patients had a
dominant genotype shared among all sample types. Genotyping of serum samples
was successful in two serum samples with galactomannan ratios of 4 and 5.6, but
failed in serum samples with galactomannan levels <0.5. In addition, testing a subset
of these materials with the AsperGenius multiplex qPCR assay, we did not find azole
resistance mutations. With this STRAf assay, A. fumigatus from FFPE tissue and serum
was successfully genotyped, allowing retrospective examination of A. fumigatus in culture
negative patients with IA.
Keywords: Aspergillus fumigatus, molecular detection, molecular typing, paraffin embedded formalin fixed tissue,
serum
INTRODUCTION
The genus Aspergillus consists of more than 300 species of spore-forming filamentous fungi, but
only a few species are recognized as human pathogens (Paulussen et al., 2017). While healthy
individuals are generally not affected, immunocompromised persons are at risk to develop invasive
aspergillosis (IA) with high mortality rates (Ullmann et al., 2018). Aspergillus fumigatus is the most
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prevalent species within the genus Aspergillus and the major
species causing this disease, although there are also other
Aspergillus species, which can cause IA (Sugui et al., 2014).
The diagnosis of IA is challenging as its clinical symptoms,
including fever, cough, respiratory secretions, and dyspnea
are not specific for this disease. Readily available respiratory
samples, like sputum and bronchoalveolar lavage (BAL) fluid,
can be cultured or directly tested for the presence of Aspergillus
species, however positive specimens may reflect environmental
contamination or colonization of the airway instead of invasive
infection (Rantakokko-Jalava et al., 2003; Springer et al., 2018b).
To improve the quality of clinical studies, guidelines have been
established by the European Organization for Research and
Treatment of Cancer/Mycosis Study Group (EORTC/MSG) to
diagnose IA by categorizing this invasive fungal disease in
“proven,” “probable,” or “possible” (De Pauw et al., 2008). Proven
IA requires the histopathological identification of hyphae in
a needle aspiration or biopsy accompanied by tissue damage
and culture from a tissue that is normally sterile, followed
by identification of the Aspergillus. Probable IA is based on a
combination of host factors, clinical features and mycological
criteria, while with possible IA these mycological criteria are
not required. Mycological criteria include the identification of
Aspergillus species in respiratory samples or their cultures or the
presence of galactomannan (GM) antigen, a component of the
Aspergillus cell wall (Mennink-Kersten et al., 2004; Boch et al.,
2016; Eigl et al., 2017), in serum, plasma, or BAL fluid (De Pauw
et al., 2008). Due to difficulties to use these diagnostic criteria for
intensive care patients, an additional classification of “putative”
IA was established, which besides a positive culture of lower
respiratory tract specimen, is based on clinical signs and host
factors or mycological criteria (Blot et al., 2012).
Different Aspergillus species have variable susceptibility for
antifungal drugs and therefore it is important to identify the
species causing IA, preferentially using deep tissue biopsies to
be certain that the fungus recovered is causing the infection.
For histopathological purposes, such tissues are mostly fixed
with formalin and embedded in paraffin (Ullmann et al.,
2018). Microscopic examination is sometimes challenging,
especially for Aspergillus species, leading quite frequently to
an incorrect morphological diagnosis (Kung et al., 2018).
Recent advances allowed the isolation of fungal DNA from
formalin-fixed paraffin-embedded (FFPE) tissues and, using
qPCR, the identification of the fungal pathogens to species level
(O’Sullivan et al., 2003; Rantakokko-Jalava et al., 2003; Perlin and
Wiederhold, 2017). This has also been shown for samples with
Aspergillus (Salehi et al., 2016; Dannaoui et al., 2017; Dudakova
et al., 2017; Barnes et al., 2018; Morio et al., 2018; Springer
et al., 2018a). To obtain closer insight in the epidemiology and
pathogenesis of IA, it is essential to characterize Aspergillus
strains genetically from different tissues from patients with IA.
Different high discriminatory typing techniques for A. fumigatus
are available (de Valk et al., 2007). As human DNA is also present
in tissue and serum samples, such genotyping assay should be
species-specific, making AFLP (de Valk et al., 2007) and RISC (de
Ruiter et al., 2007) typing unsuitable. In contrast, microsatellite
typing using the STRAf assay only amplifies specific A. fumigatus
targets and the method is highly discriminative (de Valk et al.,
2005). In this study we investigated whether it is possible to
genotype A. fumigatus with high-resolution STRAf typing (de
Valk et al., 2005) in FFPE tissue and serum samples.
MATERIALS AND METHODS
Patients
Isolates, FFPE tissue and serum samples from five ICU patients
(A-E) in the age of 58 to 67 years old, were collected. All
five patients had histological proven IA and were treated with
antifungals. An overview of the patients is given in Table 1.
DNA Extraction From Serum and FFPE
Tissue Samples
DNA was extracted from 200 µl serum using the High Viral
Nucleic Acid Kit (Roche Diagnostics, Almere, The Netherlands)
according to manufacturer instructions. For the FFPE lung and
bronchial biopsies, 5 sections (thickness, 10µM) were cut using a
sterile microtome blade and transferred to a 2ml centrifuge tube.
To remove paraffin wax, the samples were washed with 2x 500 µl
xylene, 2x 500 µl ethanol absolute and 500 µl acetone. The pellet
was dried at 56◦C. Next, 300 µl of Puregene cell lysis solution
fromGentra Systems (Biozym B.V., Landgraaf, The Netherlands)
and Proteïnase K was added and incubated overnight at 56◦C
with continue mixing. Following mechanical lysis by running
the sample for 30 s at 6,500 rpm in a MagNA Lyser instrument
with MagNA Lyser Green Beads (Roche Diagnostics), DNA was
purified using affinity chromatography and subsequently eluted
with 10mM Tris-HCl, 1mM EDTA (Boom et al., 1990).
A. fumigatus Isolates and DNA Extraction
Samples obtained from patients were routinely cultured on
Sabouraud agar for 7 days at 30 and 35◦C. A. fumigatus
isolates were presumptively identified at the time of collection
by macroscopic and microscopic characteristics and the ability
to grow at 48◦C. The isolates were stored as spore suspensions
in regular microbial freezing broth containing 12.5% (vol/vol)
glycerol at −80◦C until testing. The isolates were revived by
scraping off part of the sample, plating on Sabouraud’s agar and
cultivated at 30◦C until sporulation. DNA from A. fumigatus
TABLE 1 | Patients with histologically proven invasive aspergillosis.
Patient Age Underlying disease Diagnosis Treatment Outcome




















D 58 COPD Subacute
IA
Itraconazole Survived
E 65 COPD Pulmonary
IA
Itraconazole Survived
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TABLE 2 | Overview of typing results.
Pat. + no. Origin Day of isolation Cultured isolate STRAf type
2A 2B 2C 3A 3B 3C 4A 4B 4C
A1 Sputum 0 Yes 25 22 19 28 9 27 10 9 5
A2 Sputum 2 Yes 25 22 19 28 9 27 10 9 5
A3 Serum, GM 0.1 3 No neg neg neg neg neg neg neg neg neg
A4 Serum, GM 0.1 6 No neg neg neg neg neg neg neg neg neg
A5 Sputum 7 Yes 25 22 19 28 9 27 10 9 5
A6 Lung abscess 7 Yes 23 21 8 46 9 6 8 9 5
A7 Sputum 7 Yes 25 22 19 28 9 27 10 9 5
A8 Biopsy lung 7 No > 3 genotypes* > 3 genotypes* > 3 genotypes*
A9 BAL 9 Yes 25 22 19 28 9 27 10 9 5
A10 Biopsy lung 9 No > 3 genotypes* > 3 genotypes* > 3 genotypes*
A11 Biopsy lung 9 No neg 22 19 28 9 27 10 9 5
B1 Sputum 0 Yes 18 12 8 28 10 18 9 8 5
B2 Sputum 1 Yes 18 12 8 28 10 18 9 8 5
B3 Sputum 3 Yes 18 12 8 28 10 18 9 8 5
B4 Sputum 7 Yes 18 12 8 28 10 18 9 8 5
B5 Sputum 10 Yes 18 12 8 28 10 18 9 8 5
B6 Sputum 14 Yes 18 12 8 28 10 18 9 8 5
B7 Sputum 16 Yes 18 12 8 28 10 18 9 8 5
B8 Sputum 20 Yes 18 12 8 28 10 18 9 8 5
B9 Sputum 30 Yes 18 12 8 28 10 18 9 8 5
B10 Serum, GM 0.4 30 No neg neg neg neg neg neg neg neg neg
B11 Sputum 31 Yes 18 12 8 28 10 18 9 8 5
B12 Sputum 35 Yes 18 12 8 28 10 18 9 8 5
B13 Sputum 38 Yes 18 12 8 28 10 18 9 8 5
B14 BAL 42 Yes 18 12 8 28 10 18 9 8 5
B15 Ascitis fluid 42 Yes 18 12 8 28 10 18 9 8 5
B16 Serum, GM 4.0 43 No 18 12 8 28 10 18 9 8 5
B17 Sputum 43 Yes 18 12 8 28 10 18 9 8 5
B18 Serum, GM 5.6 44 No 18 12 8 28 10 18 9 8 5
B19 Biopsy lung 44 No 18 12 8 28 10 18 9 8 5
C1 Sputum 0 Yes 21 25 18 27 12 7 21 10 8
C2 Sputum 0 Yes 18 20 15 28 11 21 26 26 8
C3 Bronchial biopsy 1 No neg neg 18 27 12 7 neg 10 8
C4 Serum 1 No neg neg neg neg neg neg neg neg neg
C5 Sputum 4 Yes 18 28 15 16 10 19 8 8 5
C6 Sputum 5 Yes 21 25 18 27 12 7 21 10 8
C7 Sputum 21 Yes 21 25 18 27 12 7 21 10 8
C8 Sputum 25 Yes 21 25 18 27 12 7 21 10 8
C9 Serum 25 No neg neg neg neg neg neg neg neg neg
C10 Sputum 32 Yes 21 25 18 27 12 7 21 10 8
C11 Sputum 39 Yes 21 25 18 27 12 7 21 10 8
C12 Sputum 42 Yes 21 25 18 27 12 7 21 10 8
C13 Sputum 45 Yes 21 25 18 27 12 7 21 10 8
C14 Sputum 46 Yes 21 25 18 27 12 7 21 10 8
C15 Sputum 49 Yes 21 25 18 27 12 7 21 10 8
C16 Sputum 54 Yes 21 25 18 27 12 7 21 10 8
C17 Sputum 61 Yes 21 25 18 27 12 7 21 10 8
C18 Sputum 63 Yes 21 25 18 27 12 7 21 10 8
C19 Sputum 68 Yes 21 25 18 27 12 7 21 10 8
(Continued)
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TABLE 2 | Continued
Pat. + no. Origin Day of isolation Cultured isolate STRAf type
2A 2B 2C 3A 3B 3C 4A 4B 4C
C20 Sputum 71 Yes 21 25 18 27 12 7 21 10 8
C21 Sputum 75 Yes 21 25 18 27 12 7 21 10 8
C22 Sputum 75 Yes 18 12 18 27 22 21 18 9 5
C23 Serum 76 No neg neg neg neg neg neg neg neg neg
C24 Sputum 76 Yes 21 25 18 27 12 7 21 10 8
C25 Serum 77 No neg neg neg neg neg neg neg neg neg
C26 Sputum 79 Yes 21 25 18 27 12 7 21 10 8
C27 Sputum 79 Yes 21 25 18 27 12 7 21 10 8
C28 Bronchial biopsy 79 No 21 25 18 27 12 7 21 10 8
D1 Sputum 0 Yes 11 12 17 26 21 21 14 8 5
D2 BAL 1 Yes 11 12 17 26 21 21 14 8 5
D3 BAL 1 Yes 11 12 17 26 21 21 14 8 5
D4 Biopsy lung# 3 Yes 11 12 17 26 21 21 14 8 5
D5 Lung abscess 3 Yes 11 12 17 26 21 21 14 8 5
D6 Serum 4 No neg neg neg neg neg neg neg neg neg
D7 Serum, GM 0.2 4 No neg neg neg neg neg neg neg neg neg
D8 Biopsy lung 4 No 11 12 17 26 21 21 14 8 5
E1 BAL 0 Yes 18 23 16 38 11 46 10 9 8
E2 Bronchial biopsy 0 No 18 23 16 38 11 46 10 9 8
GM, galactomannan.
FFPE tissues are underlined.
*Genotypes from these samples differed from the genotypes found in the other samples.
#Genotyping was performed on both culture as direct material. Outcome was identical.
spores was extracted and purified with the MagNA Lyzer and
MagNA Pure LC Instruments (Roche Diagnostics) as previous
described (de Valk et al., 2005).
Genotyping Using the STRAf Assay
Reaction conditions and PCR primers were as described (de Valk
et al., 2005), with minor modifications as described below. With
regard to the serum and tissue samples the volume of DNA was
raised to 5 µl for each sample, the total volume of the PCR
reaction remained 25 µl. The number of cycles was increased to
40 during the amplification procedure. Electropherograms were
analyzed using Fragment Profiler 1.2 software (GE Healthcare,
Roosendaal, The Netherlands).
AsperGenius Multiplex qPCR
The AsperGenius multiplex qPCR assay (PathoNostics,
Maastricht, the Netherlands) was used to detect Aspergillus
species, A. fumigatus and A. terreus, and identify azole
resistance CYP51A mutations TR34, L98H, Y121F and T289A in
A. fumigatus according to the instructions from themanufacturer
and as described (Chong et al., 2015). The qPCR was performed
on a LightCycler 480-II (Roche Diagnostics).
Ethics
Samples were collected during routine patient care and the
study was retrospective, therefore it was determined by the local
Institutional Review Board of the CWZ that ethical clearance
was not indicated. As patient anonymity was maintained, written
informed consent of participants was also not required.
RESULTS
From patient A, BAL, lung abscess aspirate and four sputa,
collected within a week, were cultured and genotyped by
analyzing the variability in length of 9 STRs in A. fumigatus
(STRAf ) The BAL and four sputa showed one identical genotype
of A. fumigatus, while a different genotype was obtained from
the lung abscess (Table 2). Additionally, two sera and three lung
biopsies were obtained. The serum samples, which were GM
negative, showed no signal with the STRAf assay. In two lung
biopsies different genotypes were identified, as multiple peaks
were present for all 9 STRAf markers. The genotype of the third
lung biopsy was identical to the one found in the BAL and
sputum. From patient B we genotyped A. fumigatus isolates from
13 sputa, an ascites fluid and a BAL. One A. fumigatus STRAf
type was found for all cultures and this type was also detected in
two serum samples, with GM ratios of 4.0 and 5.6, and FFPE lung
tissue. STRAf typing was not successful for a serum sample with
a GM index of 0.4.
From patient C, cultures of 22 sputum samples, isolated
during a 9-week period, were STRAf typed. Nineteen of these
A. fumigatus isolates were genotypically identical, while three
isolates demonstrated three different genotypes. Two bronchial
biopsies demonstrated a STRAf type identical to the 19 sputum
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TABLE 3 | Results of AsperGenius multiplex real-time PCR assay on subset of patient materials.















A3 Serum, GM 0.1 35.49 38.60 – - — WT WT
A4 Serum, GM 0.1 35.49 36.93 – – WT WT WT
A8 Biopsy lung 26.87 28.61 – WT WT WT WT
A10 Biopsy lung 30.80 32.55 – WT WT WT WT
A11 Biopsy lung 31.61 33.43 – WT WT WT WT
B10 Serum, GM 0.4 31.83 32.44 – – WT WT –
B16 Serum, GM 4.0 29.78 31.39 – # WT WT WT
B18 Serum, GM 5.6 32.41 33.93 – WT WT WT WT
B19 Biopsy lung – – –
C3 Bronchial biopsy 32.55 34.36 – WT WT - -
C4 Serum – – –
C9 Serum – – –
C25 Serum 36.41 38.56 – WT WT WT WT
C28 Bronchial biopsy 26.76 28.78 – WT WT WT WT
D7 Serum, GM 0.2 – – –
D8 Biopsy lung 30.70 32.45 – WT WT WT WT
E2 Bronchial biopsy 30.77 32.62 – WT WT WT WT
–, Amplification not successful.
#Melting curve differ.
cultures. Four GM negative serum samples of this patient were
also negative in the STRAf assay. In patient D STRAf typing
of five cultured A. fumigatus isolates from sputum, two BAL
samples, lung tissue and a lung abscess yielded a genotype that
was identical to the genotype obtained from FFPE lung tissue.
Two serum samples from this patient were negative for STRAf
typing. In patient E the STRAf type found in the culture from
a BAL sample was identical to the one obtained from a FFPE
bronchial biopsy (Table 2).
Finally, we investigated whether it was feasible to determine
azole resistance in a subset of available FFPE tissue and serum
samples using the AsperGenius multiplex qPCR assay. This
assays allows detection of Aspergillus in clinical materials and
subsequent identification of azole resistance mutations TR34,
L98H, Y121F, and T298A in CYP51A in case of A. fumigatus
positive sampes. From 10 samples with successful STRAf typing,
9 were found positive for both the Aspergillus species and
A. fumigatus qPCR (Table 3). From 7 sera with unsuccessful
STRAf typing (A3, A4, B10, C4, C9, C25, and D7), A. fumigatus
was identified in 4 samples using the AsperGenius qPCR.
There was no azole-resistance related mutation observed in the
A. fumigatus positive samples.
DISCUSSION
This study demonstrated that it is technically feasible to
genotype A. fumigatus directly from FFPE tissue samples from
patients with proven IA without the need to cultivate the
isolate. In three patients (B, D, and E) we observed identical
STRAf types in all sample types, including sputa and BAL
fluids, serum, and lung biopsies. In patient C a dominant
genotype was found in cultures from sputa, which was also
identified in lung tissue. In patient A, five of the six isolates
had the same genotype as detected in one of the three
lung biopsies. Remarkably, in the two other lung biopsies
more than three STRAf types were found, suggesting mixed
infection, a phenomenon described earlier (Kolwijck et al.,
2016). Interestingly, another study found that from such mixed
respiratory infections, only one strain might disseminate to
distant organs (Escribano et al., 2017). Thus, in our study the
genotype of A. fumigatus identified in non-sterile respiratory
samples largely represented those found in deeper tissues. These
results are in concordance with previous studies on fresh
materials, in which A. fumigatus isolates obtained from deeper
tissue were often identical to those from respiratory samples (de
Valk et al., 2007).
A STRAf type from serum was only obtained from patient
B. GM ratio in these serum samples was 4.0 and 5.6. In sera
from patient A, C, and D GM ratios were <0.5 and STRAf
typing was not successful. This finding suggests that successful
STRAf typing in serum requires a certain threshold level of
GM. A GM ratio threshold of >0.5 is one of the diagnostic
criteria for classification of patients with IA (De Pauw et al.,
2008; Boch et al., 2016; Eigl et al., 2017). Remarkable, only
one out of four patients with proven IA exhibited a GM
ratio of >0.5, suggesting that the sensitivity of this analysis
in the diagnosis of IA is rather low. Indeed a recent study
with twenty-six patients with proven/probable IA found that
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only 23% of patients exhibited serum GM ratio >0.5 (Boch
et al., 2016). Then, we found that from sera with unsuccessful
STRAf typing, four tested positive for A. fumigatus in the
AsperGenius multiplex qPCR and three negative, demonstrating
that in some situations STRAf typing is not successful despite
the presence of A. fumigatus DNA. STRAf typing for these
samples might be more successful if the multiplex PCR would
be divided over monoplex PCRs, which normally enhances the
individual STRAf signals. This was however not tested. Another
possibility to improve STRAf typing from blood samples is the
use of plasma instead of serum, as it was found that DNA
concentrations are higher in plasma, leading to an increased
sensitivity to detect A. fumigatus (White et al., 2015). Monoplex
PCRs were also not performed for other samples, as only in
one biopsy (C3) two dinucleotide repeats (2A and 2B) and one
tetranucleotide repeat (4A) could not be amplified, while the
six remaining loci yielded good interpretable peaks. These loci
showed identical repeat numbers as many other cultured isolates
of this patient. Therefore, these sample were considered to be
identical.
Finally, using the AsperGenius multiplex qPCR assay we
investigated the potential presence of azole resistance markers
TR34, L98H, Y121F, and T289A in lung biopsies and serum
samples positive for A. fumigatus (Chong et al., 2015). While
amplification for most samples was achieved, it did not succeed
for sample B19, although genotyping was successful. This likely
represented a false negative result, possibly resulting from
lower DNA quality. In samples with A. fumigatus no resistance
mutations were identified. In sample B16 the TR34 melting
curve did not correspond with wildtype or mutant control. This
sample was not further investigated by sequence analysis, so the
cause of this discrepancy remains unknown. Amplification of
resistance targets was not successful in 7 of 52 PCR reactions
and these materials originated from three sera and a lung biopsy.
The other six lung biopsies with A. fumigatus were successfully
characterized, demonstrating a success rate of 86% for FFPE
tissues, which is very similar to the performance of this assay in
non-FFPE clinical materials (White et al., 2017; Buil et al., 2018;
Postina et al., 2018).
In conclusion, the STRAf assay allows simultaneous detection
as well as high discriminatory genotyping ofA. fumigatus directly
in FFPE tissue samples without the need for culture. This
approach allows (retrospective) examination of A. fumigatus
in patients with IA and might be used toward a better
understanding of the pathogenesis of this disease.
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